Program
ASC36
A development code. Also written as “ASC36 Injection A, for subcutaneous use”, “ASC36 Injection B, for subcutaneous use” and “ASC36 tablets, for oral use”.
Its studies are mostly in Obesity, led by Ascletis Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ascletis Pharma | 22 open or running | phase 1since Oct 19, 2026 | Oct 19, 2026 | Apr 2027phase 1 · NCT07893106 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2026First studies: 2 phase 1 studies in ObesityFirst studyNCT07893106, NCT07893093
Ahead
- Apr 2027Primary completion: phase 1 study in ObesityNCT07893106
- Jun 2027Primary completion: phase 1 study in ObesityNCT07893093
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07893106Obesity · United States | 1 | Recruiting | Apr 2027 | 86 |
| NCT07893093Obesity · United States | 1 | Recruiting | Jun 2027 | 144 |
How it is read
Names in the registry
- “ASC36 Injection A, for subcutaneous use”, 1 entry
- “ASC36 Injection B, for subcutaneous use”, 1 entry
- “ASC36 tablets, for oral use”, 1 entry
Codes read as this program: ASC36.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.